alnuctamab (CC-93269) / BMS 
Welcome,         Profile    Billing    Logout  
 0 Diseases   0 Trials   0 Trials   0 News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
alnuctamab (CC-93269) / BMS
ALUMMINATE, NCT06232707: A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Withdrawn
3
466
Europe, Canada, Japan, US, RoW
Alnuctamab, BMS-986349, CC-93269, Pomalidomide, POMALYST®, IMNOVID®, CC-4047, BMS-986379, Daratumumab, DARZALEX®, DARZALEX, FASPRO®, Elotuzumab, Empliciti®, BMS-901608, Carfilzomib, KYPROLIS®, Dexamethasone
Celgene
Multiple Myeloma
11/25
09/30
NCT06163898: A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma

Active, not recruiting
1
156
US, RoW
Alnuctamab, BMS-986349, CC-93269, EM901, Mezigdomide, BMS-986348, CC-92480, Dexamethasone
Celgene
Multiple Myeloma
05/25
08/25
NCT06121843: A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Recruiting
1
111
Canada, US
BMS-986393, CC-95266, Alnuctamab, BMS-986349, CC-93269, EM901, Mezigdomide, BMS-986348, CC-92480, Iberdomide, BMS-986382, CC-220
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Multiple Myeloma
08/28
08/28
CC-93269-MM-001, NCT03486067: Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma

Hourglass Jun 2023 - Jun 2023 : Presentation of data from CC-93269-MM-001 trial for multiple myeloma
Checkmark Presentation of data from CC-93269-MM-001 trial for R/R multiple myeloma at ASH 2022
Dec 2022 - Dec 2022: Presentation of data from CC-93269-MM-001 trial for R/R multiple myeloma at ASH 2022
Hourglass Jan 2019 - Dec 2019 : Initiation of pivotal trial for r/r multiple myeloma
Checkmark Early data from trial for multiple myeloma at ASH 2019
More
Active, not recruiting
1
250
Europe, Japan, US
CC-93269, Alnuctamab
Celgene
Multiple Myeloma
06/29
08/29

Download Options